Liver Damage and Cardiometabolic Disorders in NAFLD
Trial Parameters
Brief Summary
Liver fibrosis is the most important prognostic factor in patients with non-alcoholic factor disease. Clinical and biological condition, as diabetes or mutation for PNPLA3, are well known factors associated with liver fibrosis onset and progression. However, little is known about biochemical factors predicting liver fibrosis evolution in large NAFLD populations.
Eligibility Criteria
Inclusion Criteria: * Patients aged 18 years old or more * Patients with at least on of the following metabolic disorders * Obesity * Diabetes * Arterial hypertension * Dyslipidemia Exclusion Criteria: * Average daily consumption of alcohol \>20 g in women and of \>30 g in men (assessed by Alcohol Use Disorders Identification Test, AUDIT; * presence of hepatitis B surface antigen and antibody to hepatitis C virus; * positive tests for autoimmune hepatitis; * cirrhosis and other chronic liver diseases; * diagnosis of oncological diseases * concomitant therapy with drugs known to promote liver steatosis (e.g. amiodarone); * other chronic infectious or autoimmune disease;